Disorders of ECF Volume: Nephrotic Syndrome



Fig. 9.1
Mechanisms of renal Na+ and water retention and edema formation in nephrotic syndrome



Experimental evidence also suggests that Na+ and water retention occur in the kidney due to an intrarenal cause independent of salt-retaining mechanisms. As a result, the plasma volume is expanded, and this overfilled plasma volume leaks into the interstitium to cause edema . This is called the “overfill” theory (Fig. 9.1). The major site for Na+ reabsorption in patients with nephrotic syndrome is the collecting duct. This formed the basis of molecular theory.

According to this theory, Na+ retention in patients with nephrotic syndrome occurs by the overactivity of the epithelial Na+ channel (ENaC) in principal cells of the collecting duct. ENaC is inhibited by amiloride. Studies also have shown that the activity of Na/K-ATPase located in the basolateral membrane of the principal cell is enhanced. The net effect is avid Na+ reabsorption. It seems that ENaC activity is increased by locally generated plasmin from plasminogen. Plasminogen is filtered at the glomerulus in nephrotic syndrome. When it reaches the cortical collecting duct, it is split into plasmin by urokinase, and plasmin activates the ENaC to reabsorb Na+, resulting in low excretion of Na+. Thus, edema is formed in nephrotic syndrome .

Finally, the roles of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) have been implicated in the formation of edema in nephrotic syndrome . The levels of both of these hormones are elevated in nephrotic syndrome; however, their diuretic and natriuretic effects are blunted, resulting in retention of Na+ and water and edema formation.


Clinical Evaluation


A brief discussion of clinical evaluation of nephrotic syndrome is presented here. The most common presentation of patients with nephrotic syndrome is leg edema. Taking history of prescribed medications, dietary salt intake, over the counter medications such as nonsteroidal anti-inflammatory drugs (NSAIDs) , dyspnea, and dizziness is an integral part of clinical evaluation.

Physical examination starts with taking blood pressure and pulse rate, and orthostatic changes, if indicated. Neck, lung, heart, and abdominal examination for JVD, crackles and pleural effusion, marked S3 and P2, and murmurs, and ascites should be performed. Examination of lower extremities for pulses, edema , and skin discoloration is extremely important.

Pertinent laboratory tests include complete blood count (CBC) , Na+, K+, Cl, HCO3 , blood urea nitrogen (BUN), creatinine, and glucose. Other tests include Ca2+, Mg2+, phosphate, and lipid panel. Urine analysis, protein to creatinine ratio, and if possible, 24-h urine for protein and creatinine, need to be ordered routinely. Serum protein electrophoresis should be ordered for protein excretion other than albumin. Routine serology (Table 9.1) is necessary.




Table 9.1
Pertinent serology in nephrotic syndrome

























Test

Comment

VDRL

Patients with positive VDRL test with nephrotic syndrome may have underlying minimal change diseases or membranous nephropathy

ASO (antistreptolysin) titers

To rule out postinfectious glomerulonephritis (GN)

Complement (C3 and C4)

Low complements in postinfectious GN, lupus nephritis, membranoproliferative GN, and cryoglobulinemia

HIV, hepatitis B and C, as indicated

To recognize the respective diseases

cANCA and pANCA

To recognize Wegener’s granulomatosis and microscopic polyarteritis


VDRL venereal disease research laboratory, cANCA cytoplasmic antineutrophil cytoplasmic antibodies, pANCA perinuclear antineutrophil cytoplasmic antibodies

Pertinent electrolyte abnormalities in patients with nephrotic syndrome are hyponatremia and hyper- or hypokalemia due to diuretic use. Anemia (< 10 g/dL) is also common in many patients with nephrotic syndrome.


Treatment




1.

Treat the underlying cause of nephrotic syndrome. Use immunosuppressive agents (steroids, cyclophosphamide, cyclosporine, mycophenolate mofetil, and other agents, as indicated).

 

2.

Restrict dietary Na+, as suggested for CHF and cirrhosis.

 

3.

Use combination of loop diuretic and amiloride to improve edema. Also, spironolactone can be used in place of amiloride.

 

4.

Restrict dietary protein intake to < 1 g/kg/day, if serum albumin is < 2 g/dL.

 

5.

Use angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) to improve proteinuria and prevent progression of renal disease .

 

Jun 20, 2017 | Posted by in NEPHROLOGY | Comments Off on Disorders of ECF Volume: Nephrotic Syndrome

Full access? Get Clinical Tree

Get Clinical Tree app for offline access